Form 8-K · Current Report · Filed 2024-09-20
Johnson & Johnson's Subsidiary Files for Chapter 11 Bankruptcy to Resolve Talc Litigation
On September 20, 2024, Johnson & Johnson's subsidiary, Red River Talc LLC, filed for a voluntary prepackaged Chapter 11 bankruptcy to resolve all current and future claims related to ovarian cancer arising from cosmetic talc litigation.
- Filer
- Johnson & Johnson JNJ · NYSE
- Filed
- Accession
- 0000200406-24-000083
- CIK
- 0000200406
- Signal
- Low impactHealthcare
- Source
- Official filing on sec.gov ↗
Details
The bankruptcy plan, supported by approximately 83% of current claimants and the Future Claims Representative, proposes a settlement of approximately $8 billion. The Company has increased its contribution to the settlement by $1.75 billion.
Items reported
Regulation FD Disclosure
Financial Statements and Exhibits
Market reaction
Close before filing
$164.82
Next session
-1.0%
Since filing
+55.5%
Latest close
$256.35
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from JNJ reporting the same item, with the next session's move:
Exhibits (1)
About Johnson & Johnson
Johnson & Johnson is a multinational corporation engaged in the research, development, production, and sale of a broad range of healthcare products. Primarily known for its pharmaceuticals, medical devices, and consumer health products, Johnson & Johnson has a significant presence in the global healthcare industry. It develops medications for a variety of fields such as immunology, oncology, neurology, infectious diseases, and vaccines. The company also produces a wide array of medical devices for surgery, orthopedics, and cardiovascular health. In addition to pharmaceuticals, Johnson & Johnson is renowned for its consumer health products, including baby care, skin and hair care, wound care, and over-the-counter pharmaceuticals, with well-recognized brands like Band-Aid, Tylenol, and Neutrogena. Operating globally, the corporation's extensive portfolio and commitment to healthcare innovation make it a pivotal player in the industry, ensuring it remains influential in addressing worldwide health challenges and advancing medical technology.
Never miss another JNJ filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.